부산대학교 도서관

The much-visited topic of endoscopic treatment of VUR in children with an injectable agent is assessed by authors from Italy. However, in this study using Macroplastique, they had a 72% success rate after the first injection, 97% after the second, and 100% after the third. What is interesting is that 68% of the cases had grade IV–V VUR. OBJECTIVE To report our experience of treating dilating vesico-ureteric reflux (VUR) in children, using an injectable form of polydimethylsiloxane (MacroplastiqueTM, MPQ; Uroplasty BV, Geleen, The Netherlands), as medical treatment for moderate or severe VUR is associated with a high proportion of persistence or development of new scars. PATIENTS AND METHODS The study included 32 children (40 ureters) with VUR; 13 (32%) were grade III, 20 (50%) grade IV and seven (18%) grade V. They were treated over a period of 42 months, 66% for some form of bladder dysfunction and 38% had associated diseases. The main indications were VUR grade, recurrent urinary tract infection and progression of reflux nephropathy. MPQ was injected under general anaesthesia via an 11 F cystoscope, × 30 objective, with a 5 F working channel. RESULTS The mean (sd) follow-up was 28.5 (10.2) months; VUR resolved in 80% of patients and improved to minimal VUR in the remaining 20%. The resolution/improvement rate was 72% after the first injection, 97% after the second and 100% after the third. There were no significant complications. CONCLUSION The endoscopic implantation of MPQ always corrected VUR even though 68% of the cases were grade IV–V. It should become the treatment of choice for severe VUR. [ABSTRACT FROM AUTHOR]